Fatty acid hydroxylase-associated neurodegeneration (FAHN) is a rare disease that exhibits brain modifications and motor dysfunctions in early childhood. The condition is caused by a homozygous or compound heterozygous mutation in (), whose encoded protein synthesizes 2-hydroxysphingolipids and 2-hydroxyglycosphingolipids and is therefore involved in sphingolipid metabolism. A few FAHN model organisms have already been established and give the first insight into symptomatic effects. However, they fail to establish the underlying cellular mechanism of FAHN so far. is an excellent model for many neurodegenerative disorders; hence, here, we have characterized and validated the first FAHN model. The investigation of loss of dfa2h lines revealed behavioral abnormalities, including motor impairment and flying disability, in addition to a shortened lifespan. Furthermore, alterations in mitochondrial dynamics, and autophagy were identified. Analyses of patient-derived fibroblasts, and rescue experiments with human FA2H, indicated that these defects are evolutionarily conserved. We thus present a FAHN model organism that provides new insights into the cellular mechanism of FAHN.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794614PMC
http://dx.doi.org/10.3389/fcell.2022.1000553DOI Listing

Publication Analysis

Top Keywords

fahn model
12
fatty acid
8
acid hydroxylase-associated
8
hydroxylase-associated neurodegeneration
8
cellular mechanism
8
mechanism fahn
8
fahn
6
model
5
model fatty
4
neurodegeneration reveals
4

Similar Publications

Aim: To investigate the natural progression of SGCE-associated myoclonus dystonia from symptom onset in childhood to early adulthood.

Method: Myoclonus and dystonia were monitored using rating scales in two cohorts of participants from Spain and the Netherlands. Individual annualized rates of change were calculated and longitudinal trends were assessed using Bayesian mixed models.

View Article and Find Full Text PDF

Background: Imbalance is the most commonly reported side effect following focused ultrasound (FUS) thalamotomy for essential tremor (ET). It remains unknown which patients are more likely to develop imbalance following FUS treatment.

Objective: To identify preoperative and treatment-related sonication parameters that are predictive of imbalance following FUS treatment.

View Article and Find Full Text PDF

Long-Term Health Outcomes of Huntington Disease and the Impact of Future Disease-Modifying Treatments: A Decision-Modeling Analysis.

Neurol Clin Pract

October 2024

The Comparative Health Outcomes (GFG), Policy, and Economics Institute, Department of Pharmacy, University of Washington, Seattle, WA and HCD Economics, Daresbury; Huntington's Disease Centre (GFG, LRM, SM, IRS), UCL Queen Square Institute of Neurology, London, United Kingdom; The University of Iowa Health Care (SJT), Iowa City, IA; European Huntington Association (JDL), Moerbeke Waas, Belgium; Clinical Department (AA), CHDI Management/CHDI Foundation, Princeton, NJ; Department of Neurology (JLH), Vanderbilt University Medical Center, Nashville, TN; HCD Economics (DOC), Daresbury, United Kingdom; and uniQure Inc. (TMA, FZ), Lexington, MA.

Background And Objectives: Disease-modifying treatments (DMTs) such as gene therapy are currently under investigation as a potential treatment for Huntington disease (HD). Our objective was to estimate the long-term natural history of HD progression and explore the potential efficacy impacts and value of a hypothetical DMT using a decision-analytic modeling framework.

Methods: We developed a health state transition model that separately analyzed 40-year-old individuals with prefunctional decline (PFD, HD Integrated Staging System [HD-ISS] stage <3, total functional score [TFC] 13), active functional decline Shoulson and Fahn category 1 (SF1, HD-ISS stage 3, TFC 13-11), and SF2 (HD-ISS stage 3, TFC 10-7).

View Article and Find Full Text PDF

Zinc for GNAO1 encephalopathy: Preclinical profiling and a clinical case.

Med

August 2024

Translational Research Center in Oncohaematology, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; School of Medicine and Life Sciences, Far Eastern Federal University, Vladivostok 690090, Russia. Electronic address:

Background: De novo pathogenic variants in GNAO1-the gene encoding the major neuronal G protein Gαo-cause pediatric encephalopathies and other neurological deficiencies largely refractory to available therapies. Zn emerged to restore guanosine triphosphate hydrolysis and cellular interactions of pathogenic Gαo; dietary zinc salt supplementation improves lifespan and motoric function in a Drosophila disease model.

Methods: Using biochemical, animal, and first-in-human studies, we provide support for the patient stratification and application of zinc acetate in GNAO1-associated disorders.

View Article and Find Full Text PDF

Outcomes of Percutaneous Endoscopic Gastrostomy in Huntington's Disease at a Tertiary Center.

Mov Disord Clin Pract

August 2024

Huntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.

Background: Clinically assisted nutrition and hydration via percutaneous endoscopic gastrostomy (PEG) is a therapeutic option to ameliorate the difficulties associated with enhanced catabolism, weight loss, and dysphagia in Huntington's disease (HD).

Objectives: The objective is to provide insights into demographics, staging (Shoulson-Fahn), complications, weight trajectories, and survival rates in people with HD (pwHD) who underwent PEG.

Methods: This retrospective study included 705 consecutive pwHD who attended our HD clinic between July 2006 and March 2024, of whom 52 underwent PEG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!